Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A coupla new ones from someone who reads this board regularly but seldom posts. Any comments/insights on these would be appreciated: ASPZ and ONBI
"ASPZ is the only pure Macau gaming play, unlike the Sands or Wynn, as well of the $10.8 billion generated from gaming and gambling activities in Macau from Jan to Sept 2009, 87% were from baccarat tables which are the primary gaming tables at the VIP clubs at the StarWorld Hotel."
What you say may be true. But, if so, ASPZ owes its shareholders an explanation of what happened to the exotic real estate holdings we saw pictured on its web sites and described in its announcements.
Are you suggesting that these prime asian real estate holdings were somehow traded for the StarWorld gaming interest?
"does everyone know that the Starworld Hotel is the 13th largest hotel/casino in the world and it cost almost $400m to build"
Actually, I didn't have a clue. But now I may understand why this stock got so much attention today.
Whoopie!!
Looks like some serious volume kicked in towards the close.
Maybe, just maybe ...
How could combining with Marathon Healthcare benefit PDPR shareholders?
Any and all ideas would be appreciated.
http://www.registercitizen.com/articles/2008/12/27/news/doc4955d2c95b06e827225692.txt
OK so this has become another "have faith in management" kind of deal. Ah, well.
Looks like some volume kicked in today. Any chance you made contact with Dan?
Next N-Q?
Last year they filed one end of November. Is another due by the end of this month?
Yup ... I know what the pr says... but I keep hoping for some income-producing assets in addition to or in place of real estate.
Maybe this will turn out to be just what I wanted.
Maybe Asia Properties had some desirable real estate to trade.
Just a wild guess!!
This may sizzle as soon as it gets it's nasdaq listing.
I'm guessing there will be a flood of announcements.
Asia Properties Signs MOU to Acquire Macau Casino
Asia Properties Signs MOU to Acquire Macau Casino
NEWS!!
Nov. 19, 2009 (GlobeNewswire) --
HONG KONG and BELLINGHAM, Wash., Nov. 19, 2009 (GLOBE NEWSWIRE) -- Asia Properties, Inc. (API) (Pink Sheets:ASPZ) announced today that it has signed a Memorandum of Understanding "MOU" to acquire 50.13% of a Macau casino VIP club.
Sing Hou VIP Club ("Sing Hou") located in Star World Hotel has been in operation since November 2008 under a VIP Promoter sub-license from Galaxy Entertainment Group. (See http://www.starworldmacau.com/en/entertainment/vip_club.htm) Sing Hou operates VIP baccarat gaming tables and has an aggressive expansion planned for 2010. A surge of activity at Macau's baccarat tables has pushed casino revenues to a record HK$11.27 billion (US$1.45 billion) in August. Baccarat accounts for 88 percent of total Macau casino winnings in the year to September, and revenues are up by 53 percent this year.
Daniel McKinney, API's CEO, commented, "I am pleased to inform API shareholders that we are acquiring control of an established Macau VIP club casino at the top end and most profitable sector of the market. The Macau gaming market is already the largest in the world and API plans to become a significant player in the VIP sector through this acquisition. Unlike the Sands or Wynn, API is a pure Macau gaming play."
The casino acquisition will be for restricted shares and is anticipated to close before January 17, 2010. Shareholders will be advised of the acquisition details as soon as possible after the closing.
About Asia Properties, Inc.: Asia Properties, Inc. was established to develop resorts and prime real estate in Southeast Asia. API is a Nevada corporation and trades on the Pink Sheets under the symbol "ASPZ." There are currently 35,474,362 fully diluted shares consisting of 11,965,626 restricted and 23,508,736 free trading. The transfer agent is Transfer Online, Inc. of Portland, Oregon.
The Asia Properties, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=1733
For up to date corporate information about Asia Properties, Inc. contact Daniel McKinney, email: dmckinney@asiaprop.com or (http://www.asiaprop.com) For Investor Relations, call Dennis Burns. Tel 419-951-4842 email: denny@nvestrain.com www.nvestrain.com
Statements, which are not historical facts, are forward-looking statements. The Company, through its management makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessary estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors which could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements.
CONTACT: Asia Properties, Inc.
Daniel McKinney
dmckinney@asiaprop.com
http://www.asiaprop.com
Investor Relations
Dennis Burns
419-951-4842
denny@nvestrain.com
www.nvestrain.com
Does Anyone Understand
what this Proxyvote means to the ordinary PDPR shareholder?
https://materials.proxyvote.com/Approved/70532V/20091028/INFST_47750.PDF
Has anyone talked with Ken Bean about it?
I've never seen anything like this. For a while I thought it was institutional buying (when it crossed the $1 mark.) Then I suspected short covering.
Now I'm beginning to think it's the opening volley of a takeover.
Comments?
Interesting... I was not alert to the significance of their biomarker discovery service.
Honestly, when I reviewed their latest Q, I left concerned about the long term financial viability of Arrayit.
Now, instead of closing my position, I just might increase it.
Not really understanding the field of genetics but believing that many important discoveries lie soon to be revealed, the only way I feel safe investing in the area is to buy the company whose tools will be the basis for any and all future discoveries.
Sorta like owning the maker of the shovels, picks and pans that the 49ers all needed.
8K Filed Today!!??
- Current report filing (8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report : November 10, 2009
Geotec, Inc.
(Exact name of Small Business Issuer in Its Charter)
Florida
(State or Other Jurisdiction of Incorporation)
000-26315
(Commission File Number)
59-3357040
(IRS Employer Identification No.)
110 East Atlantic Avenue, Suite 200, Delray Beach, Florida 33444
(Address of Principal Executive Offices and Zip Code)
(561) 276-9960
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[__]
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[__]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[__]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[__]
Pre-commencement to medications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
Section 5 – Corporate Governance and Management
Item 5.02 Appointment of Director; Appointment of Officer.
Geotec, Inc. (“Geotec” or the “Company”), announced today the appointment of Mark C. Dorsten, age 49, to the board of directors for the Company and to the position of Chief Operating Officer. The Company has entered into a one-year contract with Mr. Dorsten that provides for annual compensation in the amount of one hundred twenty thousand dollars ($120,000.00).
For the past five (5) years Mr. Dorsten was the President and owner of Cozy Home Security, Inc., a company engaged in the business of providing home security services to private homeowners. Mr. Dorsten is a graduate of Wright State University where he received a degree in communications from the college of liberal arts. Mr. Dorsten is licensed as a general contractor in the state of Florida. Previously, he was bonded as the owner and operator of Osprey Title Company. Neither of these companies has ever had any business relationship or affiliation with Geotec. Mr. Dorsten does not presently serve as a director for (i) any other company that has a class of securities registered under the Securities Exchange Act of 1934; or (ii) any company that is registered as an investment company under the Investment Company Act of 1940. Within the last year, the Company has not been a participant in any transaction with Mr. Dorsten except for nominal payments for services rendered to the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GEOTEC, INC.
By:
/s/: Bradley T. Ray
Bradley T. Ray,
Chairman of the Board of Directors,
Chief Executive Officer
DATED: November 10, 2009.
NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceuti
NEW YORK, Oct. 30 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), announced today that the Company has completed the acquisition of China Biopharmaceuticals Holdings, Inc. (OTC:CHBP) (BULLETIN BOARD: CHBP) , a leading Chinese pharmaceutical company.
The acquisition was completed following the approval of shareholders that was obtained at a Special Meeting of Shareholders held yesterday at 11:00 am. The shareholders of China Biopharmaceuticals approved the acquisition at a meeting of its stockholders held yesterday at 9:00 am.
Robin Smith, MD, CEO of NeoStem commented, "This acquisition has been eagerly anticipated by supporters of both NeoStem and CHBP. At NeoStem, we are very excited to complete this transaction and begin our collaboration with Suzhou Erye Pharmaceutical Co. Ltd., CHBP's primary operating subsidiary. This milestone adds in a significant way to NeoStem's existing business and intellectual property platform and assists in opening international access for the Company and its clientele to advanced stem cell technologies, preeminent physicians, and innovative therapies for a growing number of conditions. We are grateful to the leaders of CHBP who have shared this vision with us, and to numerous supporters in the United States and China who have helped make this possible. We believe strongly that the combination of our two companies provides investors with a compelling growth story, that enjoys a portfolio of valuable intellectual property that enables enhanced revenue generation opportunities today and into the future."
The Company believes that the acquisition will add in a significant way to NeoStem's current and future growth prospects :
1. a. A 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd.
("Erye"), located in Suzhou, China which based on year to date performance is on track to generate for 2009 gross revenues of approximately $60 million (US) and net income of approximately $12 million.
2. b. A robust portfolio of over 100 drugs on seven cGMP lines (current Good Manufacturing Practices).
3. c. Strong customer relationships and established respected business; has been in business for more than 50 years and is respected for its quality, service and reliability.
4. d. Opens international access for the company and enables the combined entity to source drugs and treatments from each others pipeline.
5. e. Company's presence in China provides access to one of the fastest growing medical treatment markets in the world.
6. f. World class production and manufacturing capabilities with expansion capacity with SFDA approved products and cGMP certified manufacturing facilities.
7. g. Enhanced balance sheet with total assets of approximately $52.8 million.
Madame Zhang, General Manager of Erye, said, "This Merger will allow us to expand the business potential of Eyre's substantial lines of drugs, especially our proprietary small molecule drugs, and distribute them throughout China, realizing what we anticipate will be tremendous market potential. We look forward to a long and fruitful relationship with NeoStem and believe it will benefit from the large and growing China pharmaceutical market, which is expected to become the third largest drug market in the world (behind the US and Japan), and forecast to triple in size by 2013. We are excited at the opportunity to become part of a listed publicly traded company and believe that this combination will prove beneficial to shareholders."
About NeoStem, Inc.
NeoStem is engaged in the business of developing stem cell therapies, pursuing anti-aging initiatives and is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company is also the licensor of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic-like stem cells ,shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. For more information, please visit: http://www.neostem.com/.
About China Biopharmaceuticals, Inc.
The acquisition will expand the capabilities and worldwide reach of NeoStem, while providing immediate access to the largest and fastest growing healthcare treatment market in the world. China Biopharmaceutical's primary asset is a 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), located in Suzhou, China which in 2008 generated gross revenues of approximately $50 million (US) and operating income of approximately $8,000,000 (US). NeoStem's 51% controlling interest in Erye will enable it to benefit from the over 100 drugs on seven GMP lines, including small molecule drugs being manufactured by Erye. Erye has been in business for more than 50 years and is respected for its quality, service and reliability. Erye has begun its three year expansion and relocation program which is anticipated to enhance revenues, profits, and manufacturing capabilities in one of the fastest growing medical markets, the Peoples Republic of China.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Registration Statement on Form S-4/A filed with the Commission on October 6, 2009 as well as periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem, Inc.
Robin Smith, Chief Executive Officer T: 212-584-4180 Email:
DATASOURCE: NeoStem, Inc.
CONTACT: NeoStem, Inc.: Robin Smith, Chief Executive Officer,
+1-212-584-4180,
Web Site: http://www.neostem.com/
Hondaboost, thanks for the heads-up on CHFI. Just added this gem of a no-brainer to my growing china portfolio.
Nothing like an insider-controlled publicly-reporting gem who's growing assets are already worth several times today's giveaway share prices.
Anyone following FEEC?
Ken Bean must now answer at least 4 critical questions. See referenced article on 15-12G filings.
http://www.aaii.com/commentary/articles/200601_stockstrategies.cfm
In the California gold rush days, the predictable winners were the guys who sold the picks and shovels.
Has anyone succeeded in contacting them recently?
My (crossed fingers) hope is that if there's to be any significant sales promotion, it should be timed to meet the Christmas holidays.
They answer the phone. That's the good news.
When they realize it's a shareholder they say something like ... just starting a conference call. can we call you back?
If this happens to you, don't waste your time waiting for the return call!!
They're at the limit of 125 people. Trying to raise the limit right now.
2 million in profit$.
Why didn't I think of that?
Possibly because it's absolutely amazig.
Layla, very encouraging news.
Every once in a while you can find a winner in these small caps... and this looks to be one of them.
Perchance, did Ken tell you how many locations they now have? Last I looked, they were growing impressively.
Last time I was foolish enough to believe a poster who reassured the board that their great wish had come true, it cost me a few thousand dollars.
A short while ago Looking for Loot posted ...
"FDA employees stacking up shares. The Dominion has been approved just waiting for the press release."
Just how do you come to such a conclusion?
Seems to me that this is a very unusual penny stock in that it already has proven sales, distribution and support capabilities in behalf of what may be a remarkable medical breakthrough product.
Given FDA approval the day traders may sell on the news. But there can be only one real long-term direction that this stock price will see.... and it's typically represented by a vertical rising arrow.
What, this undervalued?
If your suggestion of $500,000 is true...
Just divide it by 162,878,181 shares
and multiply by a p/e of 15.
I've been here for several years... but only with a small position.
Recently I've taken advantage of the low price to increase my position substantially.
Why?? Two reasons.
1)For quite a while, it seemed to me that PDPR was caught in some kind of debt spiral where they had to issue sufficient shares each month to meet payments on their loans. When received, these shares were sold on the open market driving the share price down and down.
Several months ago, the issued shares seem to have stabilized. To me, this suggests that operating cash flows may have increased sufficiently to handle loan payments.
2)Then comes the note posted a few days ago...
Hi xxxxxx
Gag order in effect.....but the next news release will be a blockbuster. For right now, please stay sidelined...neither buy nor sell.
Best regards
Ken Bean
Any comments on my thoughts?
Reverse split or not, management has yet to address an even more serious outcome of earlier financing... 500 million outstanding warrants.
Until some form of alternate financing is announced that invalidates these warrants, the share price is at risk.
Yup, 600,000,000 authorized shares might be a sign of dilution.
But it could also show that refinancing is under way.
Or that they need sufficient shares to buy out ADMH (300,000,000 outstanding shares) and/or LGAL (130,000,000 outstanding shares.)
It's IFN on the Australian stock exchange.
Here, it's a pink sheeter IFGNF
But it's legit and nicely profitable. Even pays a nice dividend.
The only problem I have with it is that it's planning to sell its US assets.
------------
August 19, 2009 - 6:56 AM EDT
Infigen Energy plans sale of US wind farms
Aug. 19, 2009 (M2 Communications Ltd.) --
Australian renewable energy company Infigen Energy (ASX:IFN) said on Monday that it is proposing to sell all or part of its 1.069 GW wind farm portfolio in the United States.
The company is planning to accelerate its development in Australia.
The domestic ticker is IFGNF
Infigen Energy plans sale of US wind farms
Infigen Energy plans sale of US wind farms
Aug. 19, 2009 (M2 Communications Ltd.) --
Australian renewable energy company Infigen Energy (ASX:IFN) said on Monday that it is proposing to sell all or part of its 1.069 GW wind farm portfolio in the United States.
The company is planning to accelerate its development in Australia.
Infigen's managing director, Miles George, said: "The feedback from the market testing is that the qualities of Infigen's US business are highly sought after at present. It is timely for Infigen to proceed to a sale process in the US and, if appropriate, maximise returns for securityholders."
According to Infigen a number of strategic investors have indicated that they intend to invest, or increase their existing investment, in wind energy generation in the US.
Infigen Energy, which changed its name from Babcock and Brown Wind Partners in March 2009, has said previously that it has commenced a process to sell its German and French wind farm assets.
Sure sounds like BR deserves to be drawn and quartered for reckless mismanagement of a huge opportunity.
May the SEC case proceed quickly and effectively!!
Cautionupahead, thanks for the pointer. Looks to me like a great little company that used nearly toxic financing arrangements to grow to where it is.
I've taken a small opening position... but am reluctant to grow my position until after I see what the company plans to do regarding voluminous outstanding low-priced options, reverse split authorizations and increased share count.